Small study checks safety of biosimilar drug for stomach cancer
NCT ID NCT04181333
First seen Apr 22, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tested a trastuzumab biosimilar (a copy of the original drug) in 8 people with advanced or recurrent HER2-positive stomach cancer. The goal was to confirm the drug's safety and how well it works in real-world use. Researchers tracked side effects and tumor shrinkage using standard criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.